Your AI-Trained Oncology Knowledge Connection!
The China National Medical Products Administration has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.
Panayiotis S. Savvides, MD, discusses the results of the KEYNOTE-407 and IMpower131 trials and how the data have impacted the treatment of patients with stage IV squamous non–small cell lung cancer.
Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.
Jason Niu, MD, PhD, discusses the evolution in the treatment paradigm for patients with extensive-stage small cell lung cancer.
Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.
The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free survival in patients with untreated locally advanced squamous cell carcinoma of the head and neck.
Carrie L. Langstraat, MD, discusses the role of sentinel lymph node biopsy in endometrial cancer.
Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.
The first-in-class nucleotide analogue NUC-1031 has demonstrated early clinical activity in heavily pretreated patients with platinum-resistant ovarian cancer.
The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend pembrolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy.
The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.
The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.
Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.
Several faculty who were on site at the 2020 Miami Breast Cancer Conference touch upon COVID-19.
Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.
Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.
The FDA has placed a partial clinical hold on a phase I trial assessing the autologous T-cell therapy ACTR707 in combination with rituximab for patients with CD20-positive, B-cell non-Hodgkin lymphoma due to a safety concern.
Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.
Shubham Pant, MD, discusses frontline treatment selection in metastatic pancreatic cancer and shed light on some of the latest research being done in the space.
Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.
The FDA has approved the CINtec PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the cobas 4800 HPV Test.
The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab for the treatment of patients with hepatocellular carcinoma who have received prior therapy with sorafenib.
The FDA has granted a breakthrough therapy designation to JNJ-61186372 for the treatment of patients with EGFR-positive metastatic non–small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.
The triplet therapy of ixazomib, lenalidomide, and dexamethasone showed an improvement in progression-free survival, but it was not statistically significant, compared with lenalidomide/dexamethasone alone for patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant.
Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.
Kanwal Raghav, MBBS, MD, discusses the implications of molecular profiling on treatment decisions in metastatic colorectal cancer and the importance of referring patients to clinical trials.
Ahmed O. Kaseb, MD, discusses important considerations in the frontline treatment of patients with advanced hepatocellular carcinoma, the potential for targeted therapy in the space, and ongoing research with immunotherapy in earlier stages of disease.